SUMMARY: Letter to House Judiciary Committee in support of four bills, being marked up in Committee, to promote competition and consumer choice in prescription drugs, to make needed medications more avilable and affordable. The bills create clearer prohibitions against tactics brand-name drug makers use to slow or block competition from more affordable generic alternatives, and direct the FTC to conduct a thorough study of the practices of Pharmacy Benefit Managers and other intermediaries in the prescription drug supply chain.